Russell Investments Group Ltd. increased its holdings in Sarepta Therapeutics Inc (NASDAQ:SRPT) by 8.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 81,410 shares of the biotechnology company’s stock after acquiring an additional 6,240 shares during the quarter. Russell Investments Group Ltd. owned approximately 0.13% of Sarepta Therapeutics worth $3,693,000 at the end of the most recent quarter.
Several other institutional investors have also made changes to their positions in SRPT. Ameritas Investment Partners Inc. increased its holdings in shares of Sarepta Therapeutics by 6.3% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 4,561 shares of the biotechnology company’s stock valued at $154,000 after acquiring an additional 271 shares during the period. Cubist Systematic Strategies LLC increased its stake in Sarepta Therapeutics by 116.4% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 4,600 shares of the biotechnology company’s stock valued at $155,000 after buying an additional 2,474 shares during the period. Fox Run Management L.L.C. acquired a new position in Sarepta Therapeutics in the 3rd quarter valued at $204,000. Bayesian Capital Management LP acquired a new position in Sarepta Therapeutics in the 2nd quarter valued at $206,000. Finally, Strs Ohio acquired a new position in Sarepta Therapeutics in the 3rd quarter valued at $208,000. 82.02% of the stock is currently owned by institutional investors and hedge funds.
In related news, CEO Douglas S. Ingram purchased 38,138 shares of the stock in a transaction dated Wednesday, November 8th. The shares were acquired at an average cost of $52.44 per share, with a total value of $1,999,956.72. Following the purchase, the chief executive officer now directly owns 420,196 shares in the company, valued at approximately $22,035,078.24. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Hans Lennart Rudolf Wigzell sold 6,667 shares of the business’s stock in a transaction dated Thursday, November 30th. The stock was sold at an average price of $55.89, for a total transaction of $372,618.63. Following the completion of the sale, the director now owns 13,333 shares in the company, valued at $745,181.37. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 28,167 shares of company stock worth $1,497,619. Corporate insiders own 9.60% of the company’s stock.
Sarepta Therapeutics Inc (SRPT) opened at $52.60 on Friday. The company has a current ratio of 10.44, a quick ratio of 9.52 and a debt-to-equity ratio of 0.04. Sarepta Therapeutics Inc has a 12 month low of $26.26 and a 12 month high of $57.57.
Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings results on Wednesday, October 25th. The biotechnology company reported ($0.20) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.86) by $0.66. Sarepta Therapeutics had a negative net margin of 112.08% and a negative return on equity of 51.72%. The business had revenue of $45.95 million for the quarter, compared to analysts’ expectations of $41.29 million. During the same period in the prior year, the company posted ($0.95) EPS. equities research analysts forecast that Sarepta Therapeutics Inc will post -3.11 earnings per share for the current year.
SRPT has been the topic of several recent research reports. Goldman Sachs Group reissued a “buy” rating and issued a $71.00 price objective on shares of Sarepta Therapeutics in a research note on Friday, October 6th. ValuEngine cut shares of Sarepta Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, October 2nd. Oppenheimer reissued a “buy” rating on shares of Sarepta Therapeutics in a research note on Monday, September 25th. SunTrust Banks reissued a “buy” rating and issued a $56.00 price objective on shares of Sarepta Therapeutics in a research note on Thursday, September 7th. Finally, Robert W. Baird reissued a “buy” rating and issued a $101.00 price objective on shares of Sarepta Therapeutics in a research note on Tuesday, October 17th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and sixteen have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $64.14.
Sarepta Therapeutics Profile
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.